Are you thinking about diversifying your portfolio by investing in biotech? If so, companies like Gilead, Amgen and Celgene are doing well in the health sector. The most important thing to remember is that these companies invest heavily in R&D to create innovative new products. This keeps them on the cutting edge of biotech to deliver better products to the people who need them most and increase profits for shareholders.
Gilead’s stock price has slid lately, which means that you may still get a bargain price when investing in abiotech company that has traditionally been strong. This biotech company invests in finding new treatments and a possible cure for HIV/AIDS and treatments for liver diseases like Hepatitis B and C. Gilead also takes advantage of the latest cancer research to develop new treatments.
Amgen has had a good start to 2016 with its first quarter report indicating a 10% increase in revenues over the 4th quarter of 2015. Amgen’s approach to greater sales focus on creating real science-driven products that can maximize the benefits to people with serious illnesses. Amgen is one biotech company that is also taking a proactive approach to combating the problem of counterfeit drugs that can harm unwitting patients and damage the company’s reputation.
Celgene focuses on creating a strong pipeline for bringing viable new treatments from the laboratory to the marketplace. 2016 first quarter sales have grown 21% from the same quarter in 2015 and Celgene’s financial reports indicate that it is on track to meeting 2020 goals.
When looking at biotech companies, be sure to look at these Gilead, Amgen and Celgene first. These are biotech companies that are putting in a strong performance because they invest in research and development to create strong treatments and therapies that patients with serious health issues need.